LCZ696

Novartis Heart Failure Drug Gains Speedy FDA Approval
Novartis Heart Failure Drug Gains Speedy FDA Approval
Forbes
Novartis
heart failure
FDA
LCZ696
Entresto
Flag link:
Novartis' Summer Blockbuster LCZ696 Gains A Name, Skips An Advisory Panel
Novartis' Summer Blockbuster LCZ696 Gains A Name, Skips An Advisory Panel
Forbes
Novartis
LCZ696
Entresto
Flag link:
Novartis' 'megablockbuster' heart drug LCZ696 wins another rave preview
Novartis' 'megablockbuster' heart drug LCZ696 wins another rave preview
Fierce Biotech
LCZ696
Novartis
Flag link:
11 promising drugs poised to be the next billion-dollar blockbusters
11 promising drugs poised to be the next billion-dollar blockbusters
Yahoo/Business Insider
Opdivo
Praluent
LCZ696
lumacaftor
Viekira Pak
evolocumab
Gardasil 9
brexpiprazole
Toujeo
Cosentyx
Bristol-Myers Squibb
Regeneron
Sanofi
Novartis
Pfizer
AbbVie
Amge
Astellas
Merck
Otsuka
Lundbeck
Vertex Pharmaceuticals
Flag link:
Opdivo, Praluent and LCZ-696 top a launch crop poised for $27B in sales
Opdivo, Praluent and LCZ-696 top a launch crop poised for $27B in sales
Fierce Pharma Marketing
drug launches
Opdivo
Bristol-Myers Squibb
Praluent
Sanofi
Regeneron
LCZ696
Novartis
Flag link:
Why 2015 is the year of the biopharma blockbuster—with charts
Why 2015 is the year of the biopharma blockbuster—with charts
BioPharma Dive
biotech
Opdivo
Praluent
LCZ696
Ibrance
Viekira Pak
evolocumab
Gardasil 9
Bristol-Myers Squibb
Regeneron
Sanofi
Novartis
Pfizer
Vertex Pharmaceuticals
Merck
Amgen
AbbVie
Astellas
Flag link:
Novartis looks to squelch neuro worries over its would-be cardio blockbuster
Novartis looks to squelch neuro worries over its would-be cardio blockbuster
Fierce Biotech
Novartis
LCZ696
Flag link:
New research: Could Novartis CVD game-changer increase dementia risk?
New research: Could Novartis CVD game-changer increase dementia risk?
BioPharma Dive
Novartis
LCZ696
Flag link:
New Heart Drug From Novartis: Will It Raise The Risk of Alzheimer's Disease?
New Heart Drug From Novartis: Will It Raise The Risk of Alzheimer's Disease?
Forbes
Novartis
Alzheimer's disease
LCZ696
Flag link:
FirstWord Lists – The drugs that will shape 2015
FirstWord Lists – The drugs that will shape 2015
First Word Pharma
Harvoni
Viekira Pak
Gilead Sciences
AbbVie
alirocumab
evolocumab
Amgen
Regeneron
Sanofi
Opdivo
Keytruda
Merck
Bristol-Myers Squibb
Novartis
CTL019
Zarxio
Pfizer
palbociclib
Saxenda
Trulicity
Afrezza
MannKind
Eli Lilly
Novo Nordisk
LCZ696
Toujeo
Breo Ellipta
GED-0301
Celgene
BiogenIdec
Flag link:
5 Potential Blockbuster Drugs Set To Launch In 2015
5 Potential Blockbuster Drugs Set To Launch In 2015
Investors.com
Amgen
Regeneron
evolocumab
alirocumab
Alexion
asfotase alfa
Novartis
LCZ696
Pfizer
palbociclib
Flag link:
Novartis says heart-failure drug wins faster review in Europe
Novartis says heart-failure drug wins faster review in Europe
Yahoo/Reuters
Novartis
heart failure
Europe
LCZ696
Flag link:
How to prep for a 'megablockbuster' launch? Novartis lines up cost-savings data
How to prep for a 'megablockbuster' launch? Novartis lines up cost-savings data
Fierce Pharma Marketing
Novartis
LCZ696
drug launches
Flag link:
Novartis' Drug Could Change Course of Heart Failure for Patients
Novartis' Drug Could Change Course of Heart Failure for Patients
Drug Discovery and Development
Novartis
LCZ696
heart failure
Flag link:
Novartis chief says new heart failure drug will be a winner
Novartis chief says new heart failure drug will be a winner
Seeking Alpha
Novartis
Joe Jimenez
heart failure
LCZ696
Flag link:
Blockbusters Differentiate Novartis
Blockbusters Differentiate Novartis
Morningstar
Novartis
LCZ696
Flag link:
Doctors urge caution on Novartis' heart failure drug
Doctors urge caution on Novartis' heart failure drug
Pharmaphorum
Novartis
heart failure
LCZ696
Flag link:
Novartis' Game Changer: When Failure Turns To Success
Novartis' Game Changer: When Failure Turns To Success
Forbes
Novartis
heart failure
LCZ696
Flag link:
Novartis drug could be breakthrough in heart failure
Novartis drug could be breakthrough in heart failure
Pharmaforum
Novartis
heart failure
LCZ696
Flag link:
Novartis Rises Most in Five Months on Heart-Drug Trial
Novartis Rises Most in Five Months on Heart-Drug Trial
Bloomberg
Novartis
LCZ696
heart failure
Flag link:

Pages